Transcription of NEW ZEALAND DATA SHEET - Medsafe
{{id}} {{{paragraph}}}
Example: bachelor of science
NEW ZEALAND DATA SHEET - Medsafe
Version: pfddepli10718 Supersedes: pfddepli10218 Page 1 of 25 NEW ZEALAND DATA SHEET 1. PRODUCT NAME depo - medrol with lidocaine (methylprednisolone acetate (40 mg/mL), lidocaine hydrochloride monohydrate (10 mg/mL)) (depot) 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each 1 mL vial contains 40 mg/mL methylprednisolone acetate and 10 mg/mL lidocaine hydrochloride. Excipient with known effect benzyl alcohol. For the full list of excipients, see section 3. PHARMACEUTICAL FORM Injection (depot): white, aqueous, sterile suspension. 4. CLINICAL PARTICULARS Therapeutic indications depo - medrol with lidocaine by intra-articular or soft tissue administration (including periarticular and intrabursal) is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Synovitis of osteoarthritis Rheumatoid arthritis Acute gouty arthritis Epicondylitis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Acute and subacute bursitis depo - medrol
Version: pfddepli10718 Supersedes: pfddepli10218 Page 1 of 25 NEW ZEALAND DATA SHEET 1. PRODUCT NAME DEPO-MEDROL® with Lidocaine (methylprednisolone acetate (40 mg/mL), lidocaine hydrochloride monohydrate (10 mg/mL)) (depot)
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: